Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 5Other hematologic neoplasm 4Lymphoid 4Plasma cell 3Myeloid 3Breast 3Sarcoma 2Gynecologic 2Genitourinary 2CNS 2Gastrointestinal 1Classical hematology 1

Conditions

Colorectal Neoplasms 439Stomach Neoplasms 248Carcinoma, Hepatocellular 246Rectal Neoplasms 211Colonic Neoplasms 204Pancreatic Neoplasms 172Esophageal Neoplasms 113Neoplasm Metastasis 75Liver Neoplasms 71Esophageal Squamous Cell Carcinoma 64Neoplasms 63Gastrointestinal Stromal Tumors 36Cholangiocarcinoma 36Gastrointestinal Neoplasms 31Parkinson Disease 4, Autosomal Dominant Lewy Body 25Gallbladder Neoplasms 25Adenocarcinoma Of Esophagus 24Biliary Tract Neoplasms 23Anus Neoplasms 22Adenocarcinoma 21Recurrence 19Bile Duct Neoplasms 19Breast Neoplasms 18Digestive System Neoplasms 17Lung Neoplasms 13Prostatic Neoplasms 12Uterine Cervical Neoplasms 11Carcinoma 11Digestive System Diseases 10Peritoneal Neoplasms 9

Interventions

pegfilgrastim 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Fever × Gastrointestinal × Clear all
NCT00911170 2017-12-29

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Amgen

Phase 3 Completed
847 enrolled 21 charts
Classical hematologyGastrointestinal

Colonic Neoplasms, Fever, Neoplasms, Neutropenia, Rectal Neoplasms, Colorectal Neoplasms, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡